Lumira Ventures

Lumira Ventures is a venture capital firm that specializes in investing in emerging, mid, and late-stage companies within the healthcare and life sciences sectors. Founded in 2007 and based in Toronto, Ontario, with additional offices in Montreal, Vancouver, and Boston, the firm primarily focuses on biotechnology, biopharmaceuticals, medical devices, digital health, and consumer health companies. Lumira Ventures typically invests between 5 million and 15 million in North American companies, emphasizing those located in Canada and the United States. The firm is committed to helping its portfolio companies enhance the value of their technology pipelines through active board participation and support in accessing additional funding sources and market opportunities. With a history that includes investments in over 100 healthcare companies, Lumira Ventures currently manages a portfolio of more than 30 active investee companies that aim to address significant unmet needs in the healthcare landscape.

Gerry Brunk

Managing Director

Michael C. Burns

Director

Richard Glickman

Venture Partner

Lu Han

Partner

Jean Daniel Htu

MD

Daniel Hétu

Managing Director

Jacki Jenuth Ph.D

Partner & Chief Operating Officer

Vasco Larcina

CFO

Brent Norton

Venture Partner

Suman Rao

Associate

Beni Rovinski

Managing Director

Jennifer Schram

Director of Operations and Communications

Nikhil Thatte

Principal

PETER VAN DER VELDEN, MBA, MSC.

Founder & Managing General Partner

BAYE GALLIGAN, MA, HBA

Analyst

Past deals in Minnesota

HistoSonics

Series C in 2020
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.

HistoSonics

Series C in 2019
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.